Perspective Therapeutics updates corporate presentation; highlights pipeline progress

Perspective Therapeutics, Inc.

Updated presentation covers [212Pb]VMT-α-NET Phase 1/2a for NETs and [212Pb]VMT01 for melanoma.
Claims compelling anti-tumor activity, durable disease control, and best-in-class safety for NET trial.
Presentation notes upcoming data milestones but no specific dates or new financial guidance.
Pipeline includes PSV359 targeting FAP-α; supply chain with on-demand regional sites.
No material changes to business or financials disclosed in the 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.